Glaxo, Dr. Reddy's team up in emerging markets

More emerging markets news for GlaxoSmithKline: The company has forged a partnership with Dr. Reddy's Laboratories to sell more than 100 branded drugs, some of which are still in development. Dr. Reddy's would manufacture the meds; Glaxo would license and supply them to various developing countries in Africa, the Middle East, Asia Pacific and Latin America. In some markets, the drugs will be co-marketed by both companies. The deal does not include Dr. Reddy's home market of India.

Growth in emerging markets--both in population and in prosperity--is boosting demand for branded meds, Glaxo Emerging Markets President Abbas Hussain said in a statement. The alliance with Dr. Reddy's will combine the Indian firm's portfolio of branded meds with Glaxo's sales-and-marketing prowess, he said. Dr. Reddy's CEO GV Prasad added, "We are extremely pleased to combine forces with GSK, a global leader, to fully realize the potential of our strengths in technology, product development and manufacturing across a range of high growth emerging markets."

As you know, emerging-markets deals have been all the rage in pharma of late, with Glaxo among the most active; the company has acquired and licensed products, struck partnerships, and formed alliances, extending its reach in sub-Saharan Africa, China, Singapore, Argentina, Chile, Egypt, Pakistan, and a host of other emerging markets.

- read the GSK statement
- check out the story in the Wall Street Journal

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.